(HealthDay News) — Single-dose high dose-rate (HDR) brachytherapy is safe and effective for low-risk prostate cancer, according to a study presented at ESTRO 38, the annual meeting of the European Society for Radiotherapy and Oncology, held from April 26 to 30 in Milan.
Hannah Tharmalingam, from the Mount Vernon Cancer Center in Northwood, England, and colleagues treated 441 men with D’Amico classified low-risk (44 patients), intermediate-risk (285 patients), and high-risk (112 patients) prostate cancer with HDR monotherapy to a dose of 19 Gy delivered in a single treatment exposure. A total of 166 patients received androgen deprivation therapy.
Patients were followed for a median of 26 months. The researchers found 2-year biochemical progression-free survival (bPFS) rates of 100, 95, and 92% for low-risk, intermediate-risk, and high-risk patients, respectively, and 94% for all patients. The 3-year bPFS rates were 100, 86, and 75% for low-risk, intermediate-risk, and high-risk, respectively, and 88% overall. In 25 of 27 biochemical failures, the sites of relapse were radiologically identified; 15 had a local prostate recurrence. There were no serious side effects noted at the time of the treatment; however, 2 men later developed urethral strictures that required surgery and 2 men developed rectal fistulae requiring colostomy.
“This type of treatment offers an attractive alternative to surgery or other forms of radiotherapy as it has a comparatively low risk of side effects,” Tharmalingam said in a statement.
Single dose of targeted radiotherapy is safe and effective for prostate cancer [news release]. Milan, Italy. ESTRO38; April 29, 2019.